The overall mortality rate associated with all PD‐1/PD‐L1 inhibitors inducing adverse effects was about 0.45% (82/18353), but CIP was the most common reason for deaths among the ICI‐related adverse effects (irAEs) (23/82, 28.0%).2 Serious CIP is potentially life‐threatening if not treated correctly, although the overall incidence of CIP was not the highest irAE. The gene discussed is CD274; the disease is hereditary sensory and autonomic neuropathy.